Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Hypertension 1Glioblastoma 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × Ramipril × Clear all
NCT03475186 2026-03-13

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Wake Forest University Health Sciences

Phase 2 Completed
75 enrolled 47 charts
CNS

Brain Neoplasms, Glioblastoma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡